AP738A - Pyrrolidinyl Methyl indole salt. - Google Patents

Pyrrolidinyl Methyl indole salt. Download PDF

Info

Publication number
AP738A
AP738A APAP/P/1996/000801A AP9600801A AP738A AP 738 A AP738 A AP 738A AP 9600801 A AP9600801 A AP 9600801A AP 738 A AP738 A AP 738A
Authority
AP
ARIPO
Prior art keywords
fumarate salt
compound
salt
indole
fumarate
Prior art date
Application number
APAP/P/1996/000801A
Other languages
English (en)
Other versions
AP9600801A0 (en
Inventor
Martin James Wythes
Original Assignee
Pfizer Res & Development Company N V /S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Development Company N V /S A filed Critical Pfizer Res & Development Company N V /S A
Publication of AP9600801A0 publication Critical patent/AP9600801A0/xx
Application granted granted Critical
Publication of AP738A publication Critical patent/AP738A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
APAP/P/1996/000801A 1995-05-20 1996-04-11 Pyrrolidinyl Methyl indole salt. AP738A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9510223.2A GB9510223D0 (en) 1995-05-20 1995-05-20 Therapeutic agent

Publications (2)

Publication Number Publication Date
AP9600801A0 AP9600801A0 (en) 1996-04-30
AP738A true AP738A (en) 1999-03-23

Family

ID=10774766

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1996/000801A AP738A (en) 1995-05-20 1996-04-11 Pyrrolidinyl Methyl indole salt.

Country Status (42)

Country Link
US (1) US5994387A (no)
EP (1) EP0827503B1 (no)
JP (1) JP3233940B2 (no)
KR (1) KR100295255B1 (no)
CN (1) CN1063175C (no)
AP (1) AP738A (no)
AR (1) AR003949A1 (no)
AT (1) ATE194986T1 (no)
AU (1) AU701154B2 (no)
BG (1) BG63046B1 (no)
BR (1) BR9610858A (no)
CA (1) CA2219631C (no)
CO (1) CO5040221A1 (no)
CZ (1) CZ287939B6 (no)
DE (1) DE69609504T2 (no)
DK (1) DK0827503T3 (no)
DZ (1) DZ2034A1 (no)
ES (1) ES2148753T3 (no)
GB (1) GB9510223D0 (no)
GR (1) GR3034290T3 (no)
HK (1) HK1017884A1 (no)
HR (1) HRP960223B1 (no)
HU (1) HU217657B (no)
IL (1) IL118239A (no)
IS (1) IS1908B (no)
LV (1) LV11992B (no)
MA (1) MA23876A1 (no)
MX (1) MX9708966A (no)
MY (1) MY132066A (no)
NO (1) NO312068B1 (no)
NZ (1) NZ306448A (no)
OA (1) OA10747A (no)
PL (1) PL183142B1 (no)
PT (1) PT827503E (no)
RU (1) RU2161618C2 (no)
SK (1) SK281782B6 (no)
TN (1) TNSN96074A1 (no)
TR (1) TR199701397T1 (no)
UA (1) UA44320C2 (no)
WO (1) WO1996036632A1 (no)
YU (1) YU29496A (no)
ZA (1) ZA963938B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825988D0 (en) * 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3906406C1 (no) * 1989-03-01 1990-10-25 Goedecke Ag, 1000 Berlin, De
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives

Also Published As

Publication number Publication date
HUP9801761A3 (en) 1999-06-28
CZ364897A3 (cs) 1998-11-11
NO975210L (no) 1997-11-13
KR19990014934A (ko) 1999-02-25
UA44320C2 (uk) 2002-02-15
CZ287939B6 (cs) 2001-03-14
HRP960223A2 (en) 1997-10-31
NO312068B1 (no) 2002-03-11
NO975210D0 (no) 1997-11-13
DE69609504T2 (de) 2000-12-14
ZA963938B (en) 1997-11-17
SK281782B6 (sk) 2001-07-10
HRP960223B1 (en) 2000-12-31
MY132066A (en) 2007-09-28
LV11992A (lv) 1998-03-20
HUP9801761A2 (hu) 1999-05-28
PL323143A1 (en) 1998-03-16
DK0827503T3 (da) 2000-11-20
BG102053A (en) 1998-06-30
US5994387A (en) 1999-11-30
RU2161618C2 (ru) 2001-01-10
IS1908B (is) 2003-12-31
PL183142B1 (pl) 2002-05-31
JP3233940B2 (ja) 2001-12-04
MA23876A1 (fr) 1996-12-31
GR3034290T3 (en) 2000-12-29
EP0827503B1 (en) 2000-07-26
HU217657B (hu) 2000-03-28
JPH10506639A (ja) 1998-06-30
AP9600801A0 (en) 1996-04-30
CO5040221A1 (es) 2001-05-29
CN1063175C (zh) 2001-03-14
AU5500596A (en) 1996-11-29
ES2148753T3 (es) 2000-10-16
IL118239A0 (en) 1996-09-12
KR100295255B1 (ko) 2001-08-07
ATE194986T1 (de) 2000-08-15
GB9510223D0 (en) 1995-07-19
HK1017884A1 (en) 1999-12-03
EP0827503A1 (en) 1998-03-11
LV11992B (en) 1998-06-20
BR9610858A (pt) 1999-07-13
OA10747A (en) 2002-12-11
MX9708966A (es) 1998-03-31
PT827503E (pt) 2000-11-30
CN1185152A (zh) 1998-06-17
TR199701397T1 (xx) 1998-03-21
TNSN96074A1 (fr) 2005-03-15
WO1996036632A1 (en) 1996-11-21
SK154197A3 (en) 1999-01-11
DE69609504D1 (de) 2000-08-31
IS4605A (is) 1997-10-30
AR003949A1 (es) 1998-09-30
AU701154B2 (en) 1999-01-21
DZ2034A1 (fr) 2002-07-21
YU29496A (sh) 1998-12-23
BG63046B1 (bg) 2001-02-28
IL118239A (en) 2000-10-31
NZ306448A (en) 1998-10-28
CA2219631C (en) 2001-01-23
CA2219631A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
JP4948392B2 (ja) 固形薬学的組成物を調製するためのプロセス
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
JP2022521081A (ja) Ｈｂｖ感染若しくはｈｂｖ誘導性疾患の治療において有用なアミド誘導体
KR100667721B1 (ko) 제어 범위 내의 ｐｈ를 갖는 안정한 가바펜틴
US6531509B2 (en) Stable gabapentin containing more than 20 ppm of chlorine ion
US8202898B1 (en) Pharmaceutical composition
AP738A (en) Pyrrolidinyl Methyl indole salt.
US8242265B2 (en) Purification process comprising dissolving an organic compound in carbonated water and freeze-drying
WO2017174046A1 (en) A formulation of ixazomib citrate form 3
EP2874628A2 (en) Salts and hydrates of antipsychotics
US20230382897A1 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
CN109824574B (zh) 吲哚-3-甲酰胺类化合物及其应用
JPH0368578A (ja) ビスベンジルイソキノリン誘導体
JPH10158163A (ja) 消化管障害軽減剤